ADORA2A and Parkinson disease: Istradefylline is a non-dopaminergic, selective adenosine A2A receptor antagonist indicated in the US and Japan as adjunctive treatment to LD/decarboxylase inhibitors in adults with PD experiencing OFF episodes [7–9].